Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:80522 |
Name | thyroid gland anaplastic carcinoma |
Definition | A thyroid gland carcinoma that is composed of undifferentiated cells. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer thyroid gland cancer thyroid gland carcinoma thyroid gland anaplastic carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
BRAF V600E | Dabrafenib + Trametinib | thyroid gland anaplastic carcinoma | sensitive | detail... |
BRAF V600E | Vemurafenib | thyroid gland anaplastic carcinoma | predicted - sensitive | detail... |
RET fusion | Selpercatinib | thyroid gland anaplastic carcinoma | sensitive | detail... |
RET fusion | Pralsetinib | thyroid gland anaplastic carcinoma | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03181100 | Phase II | Atezolizumab + Cobimetinib Atezolizumab + Bevacizumab Atezolizumab + Nab-paclitaxel Atezolizumab + Cobimetinib + Vemurafenib Atezolizumab + Paclitaxel | Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer | Recruiting | USA | 0 |
NCT03733990 | Phase Ib/II | FP-1305 | A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) | Recruiting | USA | FRA | ESP | 3 |
NCT03753919 | Phase II | Durvalumab + Tremelimumab | Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial (DUTHY) | Recruiting | ESP | 0 |
NCT04238624 | Phase II | Cemiplimab + Dabrafenib + Trametinib | Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer | Recruiting | USA | 0 |
NCT04400474 | Phase II | Atezolizumab + Cabozantinib | Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study (CABATEN) | Recruiting | ESP | 0 |
NCT04420754 | Phase I | AIC100 | Study of AIC100 in Relapsed/Refractory Thyroid Cancer | Recruiting | USA | 0 |
NCT04429542 | Phase I | BCA101 BCA101 + Pembrolizumab | Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors | Recruiting | USA | CAN | 0 |
NCT04552769 | Phase II | Abemaciclib | Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer | Recruiting | USA | 0 |
NCT04675710 | Phase II | Dabrafenib + Pembrolizumab + Trametinib | Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer | Recruiting | USA | 0 |
NCT04759911 | Phase II | Selpercatinib | Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer | Recruiting | USA | 0 |
NCT05059470 | Phase II | Pembrolizumab | IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC | Active, not recruiting | USA | 0 |
NCT05119296 | Phase II | Pembrolizumab | Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer | Recruiting | USA | 0 |